Literature DB >> 23204124

Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature.

Luba Nalysnyk1, Javier Cid-Ruzafa, Philip Rotella, Dirk Esser.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia of unknown aetiology. It is a rare disease, and its incidence and prevalence are not clear. Therefore, we sought to review the published evidence on the global epidemiology of IPF. A comprehensive review of English language literature was performed by searching Medline and EMBASE for studies on IPF epidemiology published between January 1990 and August 2011. Studies providing quantitative data on IPF incidence and/or prevalence were identified and key data collected. 15 studies reporting on the incidence and/or prevalence of IPF were identified and summarised. IPF prevalence estimates in the USA varied between 14 and 27.9 cases per 100,000 population using narrow case definitions, and 42.7 and 63 per 100,000 population using broad case definitions. In Europe, IPF prevalence ranged from 1.25 to 23.4 cases per 100,000 population. The annual incidence of IPF in the USA was estimated at 6.8-8.8 per 100,000 population using narrow case definitions and 16.3-17.4 per 100,000 population using broad case definitions. In Europe, the annual incidence ranged between 0.22 and 7.4 per 100,000 population. IPF prevalence and incidence increase with age, are higher among males and appear to be on the increase in recent years. IPF is an orphan disease that affects a potentially increasing number of people in Europe and the USA. The observed variability in IPF incidence and prevalence may be explained by the differences in diagnostic criteria used, case definition, study population and study design.

Entities:  

Mesh:

Year:  2012        PMID: 23204124     DOI: 10.1183/09059180.00002512

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  162 in total

1.  Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.

Authors:  Boris Duchemann; Isabella Annesi-Maesano; Camille Jacobe de Naurois; Shreosi Sanyal; Pierre-Yves Brillet; Michel Brauner; Marianne Kambouchner; Sophie Huynh; Jean Marc Naccache; Raphael Borie; Jacques Piquet; Arsène Mekinian; Jerôme Virally; Yurdagul Uzunhan; Jacques Cadranel; Bruno Crestani; Olivier Fain; Francois Lhote; Robin Dhote; Nathalie Saidenberg-Kermanac'h; Paul-André Rosental; Dominique Valeyre; Hilario Nunes
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

2.  Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imaging.

Authors:  Na Sun; Isis E Fernandez; Mian Wei; Yin Wu; Michaela Aichler; Oliver Eickelberg; Axel Walch
Journal:  Histochem Cell Biol       Date:  2015-12-08       Impact factor: 4.304

3.  miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2.

Authors:  Marta Fierro-Fernández; Óscar Busnadiego; Pilar Sandoval; Cristina Espinosa-Díez; Eva Blanco-Ruiz; Macarena Rodríguez; Héctor Pian; Ricardo Ramos; Manuel López-Cabrera; Maria Laura García-Bermejo; Santiago Lamas
Journal:  EMBO Rep       Date:  2015-08-27       Impact factor: 8.807

4.  Survey of Physician's Knowledge, Attitudes, and Practices Regarding Idiopathic Pulmonary Fibrosis in Turkey.

Authors:  Haluk Türktaş; Gülfer Okumuş; Oğuz Uzun; Özlem Özdemir Kumbasar; Göksel Altınışık; Züleyha Bingöl; Şermin Börekçi; Vincent Cottin; Benan Müsellim
Journal:  Turk Thorac J       Date:  2020-01-01

5.  Diallyl disulfide inhibits proliferation and transdifferentiation of lung fibroblasts through induction of cyclooxygenase and synthesis of prostaglandin E₂.

Authors:  Yanhua Wang; Rong Cao; Bo Wei; Xiaoyu Chai; Dan Sun; Y Guan; Xin-min Liu
Journal:  Mol Cell Biochem       Date:  2014-04-23       Impact factor: 3.396

Review 6.  Idiopathic pulmonary fibrosis and a role for autoimmunity.

Authors:  Gerard F Hoyne; Hannah Elliott; Steven E Mutsaers; Cecilia M Prêle
Journal:  Immunol Cell Biol       Date:  2017-03-30       Impact factor: 5.126

Review 7.  Idiopathic pulmonary fibrosis in East Asian.

Authors:  Changbo Sun; Yanbin Sun; Hui Shen; Chunlu Yang; Shun Xu
Journal:  Intractable Rare Dis Res       Date:  2017-05

Review 8.  The diagnosis and treatment of idiopathic pulmonary fibrosis.

Authors:  Jürgen Behr
Journal:  Dtsch Arztebl Int       Date:  2013-12-23       Impact factor: 5.594

9.  The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.

Authors:  Bintou A Ahidjo; Mariama C Maiga; Elizabeth A Ihms; Mamoudou Maiga; Alvaro A Ordonez; Laurene S Cheung; Sarah Beck; Bruno B Andrade; Sanjay Jain; William R Bishai
Journal:  JCI Insight       Date:  2016-09-08

10.  Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care.

Authors:  Sergio Harari; Michele Davì; Alice Biffi; Antonella Caminati; Alessandra Ghirardini; Valeria Lovato; Claudio Cricelli; Francesco Lapi
Journal:  Intern Emerg Med       Date:  2019-09-20       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.